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death associated with CAP and AKI was 
attenuated over the fi rst 3 months, a fi nd-
ing that brings to mind accele rated fail-
ure time models for survival analysis. 25 
 The findings of Murugan and col-
leagues 22 highlight the many unanswered 
questions surrounding AKI. Th ese range 
from pre-hospitalization risk factors to 
post-hospitalization risk for end-stage 
renal disease. Data from large-scale, rig-
orously designed, community-based epi-
demiological studies are clearly needed to 
identify the risk factors for AKI. Such 
data should provide key components for 
the development of algorithms for the 
early identifi cation of patients at high risk 
for AKI. Furthermore, well-designed 
studies are needed to assess the outcomes 
following hospitalization with AKI. In 
conclusion, we applaud Murugan and 
colleagues 22 for their study, which extends 
the range of interest in AKI outside of the 
intensive care unit, and we hope that it 
leads to additional studies that will 
uncover the causes and consequences of 
AKI and improve patient care. 
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 Glomerular filtration rate (GFR) is 
 generally accepted to refl ect the number 
of normally functioning glomeruli in the 
kidney. For this reason, GFR is an impor-
tant parameter used to assess renal 
 function in both clinical medicine and 
animal models of kidney disease. 1 Accu-
rate  measurement of GFR is critical for 
determining the severity of kidney injury, 
determining the effi  cacy of therapy aimed 
at slowing progressive renal disease, and 
making clinical decisions regarding 
patient care. Estimated GFR is commonly 
used to determine whether a patient can 
tolerate a drug or imaging contrast mate-
rial, and when a kidney disease patient 
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needs to receive dialysis. 2 Th us, over- or 
underestimation of GFR may result in dire 
clinical consequences depending on the 
clinical setting. For this reason, much 
attention has been paid to characteriza-
tion of the accuracy of GFR measurements 
in the clinic. It is only recently that similar 
attention has been paid to the assessment 
of the accuracy of renal-function determi-
nation in mice. 
 Mouse models of kidney diseases have 
been increasingly used to elucidate the 
mechanisms of kidney diseases and to 
develop innovative drug therapy for pro-
gressive renal failure. As GFR is a key 
measure of therapeutic effi  cacy for drugs 
to treat chronic kidney disease in the 
clinic, accurate measurement of GFR 
eff ects is a critical parameter for transla-
tional drug discovery in preclinical mouse 
models of kidney disease. 
 Several techniques have been used to 
measure GFR in humans. These 
approaches quantify the urinary excretion 
of a tracer that, ideally, is excreted solely by 
glomerular filtration and is neither 
secreted nor reabsorbed by tubules. With 
constant infusion, or a constant endog-
enous production rate, the steady-state 
plasma level of such a substance is deter-
mined by GFR. Non-steady-state methods 
may also be used to determine GFR based 
on plasma disappearance rate of the tracer 
following a bolus injection of the tracer. 1 
Several molecules meeting these criteria 
for a marker of GFR have been studied, 
including the endogenous molecules cre-
atinine and cystatin C, and exogenously 
infused molecules such as inulin, iothala-
mate, iohexol, and radioactive markers 
( 125 I-iothalamate,  99m Tc-DTPA,  51 Cr-
EDTA). Inulin is a fructose polysaccharide 
that meets all the criteria for an ideal tracer 
for GFR. Th us inulin clearance is consid-
ered the gold standard for GFR measure-
ment in both clinical and animal studies. 
However, the utility of inulin clearance 
determinations in the clinic is limited by 
the requirement of intravenous adminis-
tration, as well as concomitant timed urine 
sample collection. Non- creatinine endog-
enous markers of GFR have not been 
widely used in the clinic, because of either 
molecule-specifi c limitations or incom-
plete clinical validation. In contrast, serum 
creatinine and creatinine clearance are 
widely used for GFR estimation in clinical 
medicine, in part because their limitations 
are well understood. 1 – 3 Similar validation 
of serum creatinine as a measure of GFR 
in mouse models of kidney disease is lack-
ing. Despite this lack of validation, the 
measurement of plasma creatinine and 
creatinine clearance has been widely 
adopted as a method to estimate GFR in 
mouse models of kidney disease. On the 
basis of a PubMed search, in the past fi ve 
years, out of 185 publications measuring 
GFR in mice, at least 56 used creatinine 
clearance. Furthermore, recent studies 
have confi rmed that the methods used to 
determine serum creatinine measurement 
in mice require special attention. 4 
 Creatinine is a metabolite of creatine, 
primarily produced in skeletal muscle. 
With a molecular weight of 113.12  Da, 
creatinine is freely filtered by the 
glomerulus. Furthermore, at least in 
humans, its production is fairly constant 
and proportional to the total muscle 
mass. When kidney function is normal, 
plasma creatinine is removed solely 
by renal excretion. While the majority 
of creatinine is excreted into the urine 
by glomerular filtration, the renal 
tubules  (primarily proximal tubules) 
also secrete a fi nite amount of creati-
nine. 1 – 3 In healthy humans, secreted 
creatinine may account for 10 – 20 % of 
urinary creatinine excretion, resulting 
in overestimation of GFR, as measured 
by creatinine clearance 1,5 ( Figure 1 ). 
Notably, in renal disease accompanied by 
diminished GFR, the contribution of 
tubular creatinine secretion to creati-
nine clearance may be dramatically 
increased and equal the contribution of 
glomerular fi ltration, 1,5 resulting in pro-
found overestimation of GFR. Con-
versely, in certain clinical settings (for 
example, decompensated heart disease 
or uncontrolled diabetes), renal tubules 
primarily reabsorb creatinine. 3 
 In contrast to the well-defi ned handling 
of creatinine by the human kidney, the 
mechanisms contributing to renal 
 creatinine excretion in the normal or 
diseased mouse are poorly characterized. 
Eisner  et al. 6 (this issue) provide impor-
tant evidence that, in normal healthy 
mice, renal creatinine secretion mark-
edly exceeds that typically seen in 
healthy humans. Comparing inulin 
clearance to creatinine clearance in indi-
vidual C57BL / 6J mice (plasma creatinine 
was measured by high-pressure liquid 
chromatography), they found that creati-
nine clearance was approximately twofold 
higher than inulin clearance (FITC-inulin 
clearance 215 ± 34, creatinine clearance 
508 ± 98   l / min in male mice; FITC-inulin 
clearance 328 ± 21, creatinine clearance 
601 ± 38   l / min in female mice). Admini-
stration of cimetidine, which blocks tubular 
creatinine secretion, signifi cantly reduced 
creatinine clearance, bringing creatinine 
clearance values more in line with the 
measured rates of inulin clearance. On the 
basis of these data, the authors estimate 
that renal tubular secretion accounts for 
about 35 – 50 % of excreted creatinine in 
healthy female and male mice. Th us, the 
rate of creatinine secretion in healthy 
mice is signifi cantly greater than that in 
healthy humans. Finally, the authors 
infused exogenous creatinine and found 
that increased plasma creatinine was 
associated with increased renal creatinine 
secretion, suggesting that in mice, as in 
humans, the contribution of the tubular 
secretion of creatinine to its clearance is 
likely to be increased in the setting of 
renal disease accompanied by elevated 
plasma creatinine concentrations. Th us, 
creatinine clearance in mice signifi cantly 
overestimates GFR. 
 Th e use of creatinine in mice is also sig-
nifi cantly complicated by artifacts in the 
techniques commonly used to measure 
plasma creatinine in mice. Traditionally, 
creatinine has been measured by the alka-
line picrate method developed by Jaff e in 
1886, in which creatinine reacts with 
picrate ions under alkaline conditions to 
form an equimolar red-colored product. 
However, many non-creatinine chrom-
agens exist in human plasma, including 
glucose and ketoacids, that interfere with 
the picrate reaction, resulting in approxi-
mately 20 % overestimation of creatinine. 
In disease states, such as diabetic keto-
acidosis, this overestimation becomes 
even more pronounced. In mice, cross-
reacting chromagens  contribute sub-
stantially more to the picrate-based 
measurement of serum creatinine than 
they do in humans. Recent studies have 
emphasized the inaccuracy of picric 
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acid-based methods to measure serum 
creatinine in mice. 4,7,8 The contribution 
of these artifacts to measurements of 
serum creatinine concentration by the 
Jaffe method in serum of healthy mice 
is typically threefold more than the con-
tribution of authentic creatinine 
( ~ 0.4  mg / dl by the Jaffe method versus 
0.07 – 0.1  mg / dl by high-pressure liquid 
chromatography or liquid chromatography /
 mass spectro scopy). 4,6,7,9 Th e fi ndings of 
Eisner  et al. 6 further cast doubt on the 
utility of creatinine as a marker of GFR in 
murine models. 
 Steady-state serum creatinine values 
have been widely used in clinical medicine 
to estimate kidney function. However, 
serum creatinine levels alone should not 
be used to assess the stage of chronic kid-
ney disease. 1 Shemesh  et al. 5 measured 
serum creatinine and inulin clearance in 
patients with chronic kidney disease and 
found that serum creatinine can remain 
less than 2.0  mg / dl in some patients 
despite reduction of GFR to as low as 
30 – 40  ml / min / 1.73  m 2 . Th is fi nding has 
been confi rmed by many other clinical 
studies. 1 Similar studies establishing the 
sensitivity of serum creatinine versus GFR 
in mice have not been defi ned. 
 Th e clinical utility of serum creatinine 
and creatinine clearance to defi ne renal 
function depends on the relatively con-
stant endogenous production of creati-
nine. Steady-state plasma creatinine 
concentration is closely correlated with 
lean body mass, and daily creatinine excre-
tion is relatively constant. 2 Precisely how 
serum creatinine is aff ected by body mass 
and other factors in mice remains to be 
determined. For example, body weight in 
mice may dramatically change over a short 
period of time following stress imposed by 
either an environmental change (for 
instance, from group housing to individual 
housing) or a disease state. Whether these 
changes in body weight aff ect murine cre-
atinine production has not been studied. 
 In summary, although the use of mouse 
models to study kidney disease off ers the 
theoretical advantage of an accurate 
 assessment of serial changes in renal func-
tion over time, caution must be taken in 
assuming that the commonly used meas-
urements of renal function in people 
directly translate to utility in mice. 
Although creatinine clearance theoreti-
cally provides ease of use and minimizes 
expense, its utility in mice remains ques-
tionable. Until creatinine-based approaches 
have been validated in diseased mice, inu-
lin-based GFR measurement should 
remain the gold standard for measure-
ments of GFR in mice. Until that time, 
determination of creatinine clearance to 
assess GFR in mice with kidney disease 
should be viewed with skepticism. 10 
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 Figure 1  |  Nephron processes tracers for GFR measurement. All listed tracers are filtered freely, 
but some tracers may bind to serum protein, which prevents their filtration. The question mark 
indicates that studies suggest that some tracers may be reabsorbed in renal tubules. Ccr, creatinine 
clearance; Cin, inulin clearance. 
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